BioCryst Pharma (BCRX) Does First Patient in BCX7353 APeX-1 Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Piper Jaffray Upgrades BioCryst Pharma (BCRX) to Overweight
August 12, 2016 6:25 AM EDTPiper Jaffray upgraded BioCryst Pharma (NASDAQ: BCRX) from Neutral to Overweight with a price target of $8.00 (from $5.00) after the company dosed the first patient in its APeX-1 trial of '7353.
Analyst Charles C. Duncan commented, "On Thursday Biocryst dosed the first patient in... More
